Aliquots - Research Briefs

May 24, 2022

Diabetes, cardiovascular drug targets

Targeting receptors of the inflammatory lipid signaling molecule PGE2 may offer a new way to tackle both Type 2 diabetes and cardiovascular disease, Vanderbilt researchers have discovered.

May 23, 2022

Pushing (anti-overdose) drugs

An automated alert to encourage clinicians to coprescribe naloxone for patients at risk of opioid overdose increased naloxone prescriptions per opioid prescription 16-fold.

May 19, 2022

Genetics and blood pressure

Including polygenic risk scores for blood pressure may improve predictive models to identify people at risk for treatment-resistant hypertension.

May 19, 2022

A clue to an adverse drug event in children

Considering metabolic (CYP2D6) enzyme activity score and patient age may aid in determining an individual’s risk for an adverse event with administration of the anti-arrhythmic drug propafenone.

May 10, 2022

Autism and sleep problems

Vanderbilt researchers developed a framework for using de-identified medical records to characterize sleep in people on the autism spectrum — a framework that should also be useful for studying other neurodevelopmental disorders.

May 9, 2022

Gene variants and transplant drug dose

Genotyping multiple enzymes that metabolize the immunosuppressive drug tacrolimus — common used for lung transplant recipients — is important for correct dosing of the drug, Vanderbilt researchers found.